Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Mitofusin 2 controls mitochondrial and synaptic dynamics of suprachiasmatic VIP neurons and related circadian rhythms
Milan Stoiljkovic, Jae Eun Song, Hee-kyung Hong, Heiko Endle, Luis Varela, Jonatas Catarino, Xiao-Bing Gao, Zong-Wu Liu, Peter Sotonyi, Sabrina Diano, Jonathan Cedernaes, Joseph Bass, Tamas L. Horvath
Milan Stoiljkovic, Jae Eun Song, Hee-kyung Hong, Heiko Endle, Luis Varela, Jonatas Catarino, Xiao-Bing Gao, Zong-Wu Liu, Peter Sotonyi, Sabrina Diano, Jonathan Cedernaes, Joseph Bass, Tamas L. Horvath
View: Text | PDF
Research Article Cell biology Metabolism Neuroscience

Mitofusin 2 controls mitochondrial and synaptic dynamics of suprachiasmatic VIP neurons and related circadian rhythms

  • Text
  • PDF
Abstract

Sustaining the strong rhythmic interactions between cellular adaptations and environmental cues has been posited as essential for preserving the physiological and behavioral alignment of an organism to the proper phase of the daily light/dark (LD) cycle. Here, we demonstrate that mitochondria and synaptic input organization of suprachiasmatic (SCN) vasoactive intestinal peptide–expressing (VIP-expressing) neurons showed circadian rhythmicity. Perturbed mitochondrial dynamics achieved by conditional ablation of the fusogenic protein mitofusin 2 (Mfn2) in VIP neurons caused disrupted circadian oscillation in mitochondria and synapses in SCN VIP neurons, leading to desynchronization of entrainment to the LD cycle in Mfn2-deficient mice that resulted in an advanced phase angle of their locomotor activity onset, alterations in core body temperature, and sleep-wake amount and architecture. Our data provide direct evidence of circadian SCN clock machinery dependence on high-performance, Mfn2-regulated mitochondrial dynamics in VIP neurons for maintaining the coherence in daily biological rhythms of the mammalian organism.

Authors

Milan Stoiljkovic, Jae Eun Song, Hee-kyung Hong, Heiko Endle, Luis Varela, Jonatas Catarino, Xiao-Bing Gao, Zong-Wu Liu, Peter Sotonyi, Sabrina Diano, Jonathan Cedernaes, Joseph Bass, Tamas L. Horvath

×

Figure 4

Loss of Mfn2 in VIP neurons alters the diurnal activity rhythm and activity onset.

Options: View larger image (or click on image) Download as PowerPoint
Loss of Mfn2 in VIP neurons alters the diurnal activity rhythm and activ...
(A) Representative actogram showing wheel-running activity of control and Mfn2–/–mice. Mice were maintained on a 12-hour light/12-hour dark cycle in wheel cages for 16 days prior to release to DD. (B) Free-running endogenous circadian period distributions of control and Mfn2–/– mice. (C) Representative activity profile graph of wheel-running activity. The activity profile was averaged over 12 days of LD (days 5–16). (D) Phase of activity onset relative to the dark phase and (E) distribution of activity counts in the light or dark periods and total activity in control and Mfn2–/– mice averaged for days 5–16 in the LD condition. (F) Core body temperature profiles over the entire LD cycle in the control (black) and Mfn2–/– mice (red). (G and H) Sleep-wake pattern measured during transitions from the light to the dark phase (G) and the dark to the light phase (H). Unfiltered EEG and EMG signals and distribution of automatically detected vigilant states in 1 control mouse and 1 Mfn2–/– mouse during the last hour of the light or dark phase, and the first 2 hours after shifting in the opposite phase. Panels on the right show extracted signals (framed in blue) in 1-minute time intervals. Red bars over the traces mark wake episodes. Inset in the red rectangle shows the EEG signal with sleep characteristic slow waves. Pie charts show the percentage distribution of wake (black), NREM (white), and REM (gray) episodes in control and Mfn2–/– mice (n = 5 for each). ZT23–00: control versus Mfn2–/– mice, P = 0.019 for wake; P = 0.014 for NREM. Unpaired 2-tailed t-test for B, D, and F (right panel); 1-way ANOVA with Tukey’s test for E; Mann Whitney test for F (left panel); multiple unpaired t-tests with Welch corrections with False Discovery Rate multiple comparisons and 2-stage step-up (Benjamini, Krieger, and Yekutieli) method for G and H. **P < 0.01, and ****P < 0.0001. (See also Supplemental Table 1 for details on the statistical information for each graph.)

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts